Leaving the study early · Siblings of people with severe mental illness
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Leaving the study early Leaving the study early: participants lost to · patients with schizophrenia
YOGA showed no clear difference in leaving the study early Leaving the study early: participants lost to compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
1 finding from 1 review
Leaving the study early · adults with schizophrenia
It is very uncertain whether ASENAPINE changes leaving the study early ‐ any reason compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
CHLORPROMAZINE may leads to lower leaving the study early compared with PLACEBO (low certainty).
1 finding from 1 review
Leaving the study early · patients with people with severe mental illnesses
SHORT showed no clear difference in leaving the study early (long term) Participants leaving the study… compared with LONG HOSPITAL STAY (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in leaving the study early ‐ short/medium term Rate of attrition compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE HIGH DOSE may leads to lower leaving the study early ‐ short/medium term Rate of attrition compared with FLUPENTHIXOL DECANOATE STANDARD DOSE (˜40 mg/IM) (low certainty).
1 finding from 1 review
Leaving the study early ‐ medium/long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes leaving the study early ‐ short term Rate of attrition compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
Perazine showed no clear difference in overall tolerability Leaving the study early due to adverse events compared with other antipsychotics (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Perazine showed no clear difference in acceptability of treatment Leaving the studies early due to any reason compared with other antipsychotics (low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early ‐ medium term ‐ any reason · patients with schizophrenia
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' showed no clear difference in leaving the study early: any reason ‐ medium term compared with ANTIPSYCHOTIC 'B' for (moderate certainty).
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review